NCT04293679View on ClinicalTrials.gov

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 21, 2019

Primary Completion Date

October 21, 2020

Study Completion Date

October 21, 2020

Conditions
Bowen's DiseaseCutaneous Squamous Cell Carcinoma in Situ
Interventions
DRUG

STP705

Investigational Product

Trial Locations (1)

33180

Center for Clinical and Cosmetic Research, Aventura

Sponsors

Lead Sponsor

Sirnaomics

Collaborators (1)

Amarex Clinical Research
All Listed Sponsors
collaborator

Amarex Clinical Research

OTHER

lead

Sirnaomics

INDUSTRY

NCT04293679 - Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC | Biotech Hunter | Biotech Hunter